Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2004CirculationOpen Access

Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does dalteparin 5000 IU once daily prevent venous thromboembolism in acutely ill medical patients?

Population

Acutely ill medical patients

Comparison

Dalteparin 5000 IU once daily vs Placebo

Design

RCT, Randomized, Placebo-controlled

Authors

ALAlain LeizoroviczVascular MedicineACAlexander T CohenSt Thomas' HospitalATAlexander G.G. TurpieVascular Medicine

Discussion

Loading...

Member takes

Implication

Supports dalteparin 5000 IU daily VTE prophylaxis in acutely ill medical patients; confirms efficacy from this RCT.

Structured PICO

Does dalteparin 5000 IU once daily prevent venous thromboembolism in acutely ill medical patients?

P
Population
Acutely ill medical patients
I
Intervention
Dalteparin 5000 IU once daily
C
Comparator
Placebo
O
Outcome
Venous thromboembolismhard clinical

Dalteparin 5000 IU once daily reduces the rate of venous thromboembolism in acutely ill medical patients with a low risk of bleeding.

Cite This Study

Leizorovicz et al. (2004) studied this question.

synapsesocial.com/papers/69dee73940ea065679559c18https://doi.org/10.1161/01.cir.0000138928.83266.24

Topics

Pulmonary embolism
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Average Partial Association in Three-Way Contingency Tables: A Review and Discussion of Alternative Tests1978 · 465 citations
  2. 2Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin1988 · 1,319 citations